Cryopreserved Platelets (CPP) for US FDA Licensure

The Defense Health Agency (DHA) Operational Medical Systems Office is issuing RFI HT9427‑26‑RFI‑705 to gather information on qualified sources capable of developing and managing cryopreserved platelets (CPP) for U.S. FDA licensure. The effort, overseen by the Warfighter Protection and Acute Care Project Management Office, is intended to produce a medical materiel solution that supports warfighter readiness and may span up to 60 months. Responders must submit a white‑paper, a rough‑order‑of‑magnitude cost estimate, and a completed contact‑information table in a single electronic file (Word or searchable PDF, ≤3 MB, ≤10 pages of narrative). Submissions must follow the specified format (12‑pt Times New Roman, single‑spaced, 1‑inch margins) and be marked as Controlled Unclassified Information (CUI) on each page. The response must include a cover page, executive summary of technical expertise, discussion of relevant capabilities and challenges, evidence of experience with the FDA, and supporting citations. All costs for preparing the response are the responder’s responsibility; no phone calls or unsolicited proposals will be accepted. Questions about the RFI are limited to one per vendor and must be submitted in writing by 3:00 PM ET on 28 April 2026; answers will be posted as a modification. Complete responses are due electronically to Peter Mitchell (peter.d.mitchell8.civ@health.mil) no later than 3:00 PM ET on 4 May 2026, with the email subject “Response to RFI for Cryopreserved Platelets (CPP).” The Government reserves the right to use any non‑proprietary information provided, to request additional data, and is under no obligation to award a contract or provide feedback.

Notice ID

e2c26dc3937049faa715f6fa7fad2308

Solicitation Number

HT9427-26-RFI-705

NAICS Code

541715

Classification Code

N/A